IRIS
CHIARELLI, LAURENT ROBERT
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.739
AS - Asia 3.591
EU - Europa 3.135
SA - Sud America 503
AF - Africa 74
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.054
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.612
CN - Cina 1.914
IE - Irlanda 842
SG - Singapore 721
HK - Hong Kong 483
RU - Federazione Russa 435
BR - Brasile 402
IT - Italia 365
FI - Finlandia 347
DE - Germania 336
UA - Ucraina 260
VN - Vietnam 177
GB - Regno Unito 149
SE - Svezia 118
CA - Canada 76
IN - India 72
FR - Francia 60
AR - Argentina 44
MX - Messico 38
AT - Austria 37
JP - Giappone 37
PL - Polonia 33
BE - Belgio 31
NL - Olanda 30
ZA - Sudafrica 26
ES - Italia 24
BD - Bangladesh 23
TR - Turchia 23
ID - Indonesia 18
IQ - Iraq 18
CZ - Repubblica Ceca 15
EG - Egitto 15
LT - Lituania 15
CL - Cile 12
UZ - Uzbekistan 12
AE - Emirati Arabi Uniti 11
AZ - Azerbaigian 11
EC - Ecuador 11
PK - Pakistan 11
SA - Arabia Saudita 11
MA - Marocco 10
VE - Venezuela 8
AU - Australia 7
CO - Colombia 7
KR - Corea 7
IR - Iran 6
LV - Lettonia 6
RO - Romania 6
GR - Grecia 5
NG - Nigeria 5
PE - Perù 5
UY - Uruguay 5
BO - Bolivia 4
LB - Libano 4
MU - Mauritius 4
PY - Paraguay 4
CR - Costa Rica 3
IL - Israele 3
MD - Moldavia 3
MY - Malesia 3
NP - Nepal 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
AL - Albania 2
AO - Angola 2
CH - Svizzera 2
DZ - Algeria 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
HU - Ungheria 2
IM - Isola di Man 2
JM - Giamaica 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
KW - Kuwait 2
KZ - Kazakistan 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
RS - Serbia 2
SN - Senegal 2
TH - Thailandia 2
TJ - Tagikistan 2
TN - Tunisia 2
AM - Armenia 1
BJ - Benin 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GH - Ghana 1
GM - Gambi 1
GT - Guatemala 1
GY - Guiana 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 12.049
Salva come PNG Salva come JPEG
Città #
Dublin 811
Chandler 676
Hong Kong 479
Ashburn 442
Beijing 433
Dallas 364
Jacksonville 353
Singapore 352
Nanjing 327
Boardman 225
Los Angeles 171
Helsinki 157
Ann Arbor 155
Nanchang 149
Princeton 135
Wilmington 135
Pavia 133
Lawrence 127
New York 116
Medford 114
Munich 111
Shenyang 102
Shanghai 95
Hebei 92
Hangzhou 90
Changsha 83
Ho Chi Minh City 72
Jiaxing 72
Moscow 71
Tianjin 67
Redondo Beach 60
Buffalo 49
Milan 48
São Paulo 39
The Dalles 38
Turku 38
Hanoi 36
Tokyo 36
Woodbridge 34
Brussels 30
Dearborn 30
Vienna 30
Warsaw 30
Santa Clara 29
Chicago 26
Denver 25
Montreal 25
Brooklyn 22
Stockholm 22
Boston 21
Falkenstein 21
Verona 21
Fairfield 20
Seattle 20
Toronto 20
London 19
Columbus 18
Houston 17
Piscataway 17
Nuremberg 16
San Francisco 16
Washington 16
Atlanta 15
Norwalk 15
Phoenix 15
San Genesio ed Uniti 15
Haiphong 14
Johannesburg 14
Guangzhou 13
Jinan 13
Orem 13
Curitiba 12
Mexico City 12
Ningbo 12
Tashkent 12
Baku 11
Chennai 11
Des Moines 11
Olomouc 11
Rio de Janeiro 11
Ottawa 10
Poplar 10
Baghdad 9
Florence 9
Menlo Park 9
New Delhi 9
St Petersburg 9
Amsterdam 8
Brasília 8
Cape Town 8
Fuzhou 8
Hyderabad 8
Kunming 8
Recife 8
Chongqing 7
Cleveland 7
Da Nang 7
Fortaleza 7
Frankfurt am Main 7
Guarulhos 7
Totale 7.991
Salva come PNG Salva come JPEG
Nome #
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1. 181
Biological and structural characterization of theMycobacterium smegmatis nitroreductase NfnB, and its rolein benzothiazinone resistance 140
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis 134
Absence of interaction between doppel and GFAP, Grb2, PrPC proteins in human tumor astrocytic cells 129
Letter to the editor regarding Shibayama et al.: Biochemical and pathophysiological characterization of Helicobacter pylori asparaginase. 128
4-Aminoquinolone Piperidine Amides: Non-Covalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity. 128
A phenotypic based target screening approach delivers new antitubercular CTP synthetase inhibitors 124
Aberrant Doppel Protein Expression in Human Astrocytic Tumors 120
Engineering of Helicobacter pylori L-asparaginase: characterization of two functionally distinct groups of mutants 118
The prion-like doppel protein is soluble in astrocytic tumor 116
Expanding targets for a metabolic therapy of cancer: L-asparaginase 116
Cell-cycle inhibition by Helicobacter pylori L-asparaginase. 116
New prodrugs against tuberculosis 115
Biochemical Characterization of Glutamate Racemase-A New Candidate Drug Target against Burkholderia cenocepacia Infections 115
Investigating the Mechanism of Action of Diketopiperazines Inhibitors of the Burkholderia cenocepacia Quorum Sensing Synthase CepI: A Site-Directed Mutagenesis Study 114
Phosphoglycerate Kinase Deficiency: Characterization of the Wild-Type Enzyme and Three Pathological Variants Generated from C.140T>a, C.491A>T and C.959G>a Mutations 113
Generation of Mutants of Helicobacter pylori L-Asparaginase 113
Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis. 112
Molecular and cellular insights into the aberrant expression of the prion protein-like gene doppel in astrocytic tumors 111
Mycobacterium tuberculosis Phosphoribosylpyrophosphate Synthetase: Biochemical Features of a Crucial Enzyme for Mycobacterial Cell Wall Biosynthesis. 110
Discovery of new diketopiperazines inhibiting Burkholderia cenocepacia quorum sensing in vitro and in vivo. 110
Rv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis. 108
BEL β-trefoil: a novel lectin with antineoplastic properties in king bolete (Boletus edulis) mushrooms. 107
Ectopic expression of the prion-like protein doppel in human astrocytoma cells 107
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK 107
Expanding Targets for a Metabolic Therapy of Cancer: L- Asparaginase 106
Chemical, Metabolic, and Cellular Characterization of a FtsZ Inhibitor Effective Against Burkholderia cenocepacia 106
Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents 106
The prion protein-like gene Doppel is aberrantly expressed in astrocytic tumors 105
New and old hot drug targets in tuberculosis 104
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG. 102
Biochemistry of Lipolytic Enzymes Secreted by Penicillium solitum and Cladosporium cladosporioides 102
Could the Oxidation of α1-Antitrypsin Prevent the Binding of Human Neutrophil Elastase in COVID-19 Patients? 101
Pyruvate kinase deficiency: Biochemical characterization of two mutations causing inability of the enzyme to properly bind substrates 101
Helicobacter pylori L-asparaginase: from Gene to Diagnostic Tool 100
Competitive fitness of essential gene knockdowns reveals a broad-spectrum antibacterial inhibitor of the cell division protein FtsZ 100
Molecular cloning and characterisation of Helicobacter pylori L-asparaginase 99
Helicobacter pylori: from gene to Diagnostic Tool 99
Biochemical signatures of doppel (Dpl) protein in human glioblastoma to support prediction in tumor malignancy 98
Burkholderia cenocepacia infections in cystic fibrosis patients: Drug resistance and therapeutic approaches 97
A new mutation of the pgk1 gene detected in an italian patient affected by phosphoglycerate kinase deficiency. 97
A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in Mycobacterium tuberculosis 97
Nuclear mRNA retention and aberrant doppel protein expression in human astrocytic tumor cells 96
ThermoFAD, a Thermofluor®-adapted flavin ad hoc detection system for protein folding and ligand binding 93
SELECTION OF MICROFUNGI WITH HIGH LIPOLYTIC ACTIVITYAND THEIR LIPASE CHARACTERIZATION 93
Molecular Insights on Pathogenic Effects of MutationsCausing Phosphoglycerate Kinase Deficiency 92
Protein Recognition by Short Peptide Reversible Inhibitors of the Chromatin-Modifying LSD1/CoREST Lysine Demethylase. 92
Structure and function of human erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia 92
Premio Ricercatissimi 2008 92
Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043 91
A new promising bactericidal compound against Burkholderia cenocepacia. 91
A new variant of phosphoglycerate kinase deficiency (p.I371K) with multiple tissue involvement: molecular and functional characterization. 91
Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug 90
Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents 89
New insights into the mechanism of action of the thienopyrimidine antitubercular prodrug TP053 89
A New Benzothiazolthiazolidine Derivative, 11726172, Is Active In Vitro, In Vivo, and against Nonreplicating Cells of Mycobacterium tuberculosis 88
Micellar electrokinetic chromatography as a complementary method to sodium dodecyl sulfate-polyacrylamide gel electrophoresis for studying limited proteolysis of proteins. 88
Characterization of a pyrimidine 5'-nucleotidase mutant form (G214R) causing hereditary hemolytic anemia. 88
The cell division protein FtsZ as a cellular target to hit cystic fibrosis pathogens 88
The allosteric regulation of pyruvate kinase. 86
An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis 86
Erythrocyte adenylate kinase deficiency: characterization of recombinant mutant forms and relationship with nonspherocytic hemolytic anemia 86
Erythrocyte Adenylate Kinase Deficiency: First In-Depth Biochemical Characterization of the Y164C Mutant Enzyme Causing Hemolytic Anemia 85
Targeting iron uptake pathway for the development of novel antitubercular drugs. 85
Improve protection to prevent infections: application of reverse vaccinology against cystic fibrosis pathogens. 85
Pyrimidine 5' Nucleotidase Deficiency: Clinical and Molecular Characterization of Two New Italian Patients 84
EXPRESSION AND CHARACTERIZATION OF THE BOVINE PRION DOPPEL 83
Aeroplane shaped crystal of a mutant ofHelicobacter pylori L-asparaginase. 83
Molecular Characterization of Three New Mutant Enzymes of Pyrimidine 5-Nucleotidase Causing Hereditary Hemolytic Anemia. 83
Inosine monophosphate dehydrogenase activity after mycophenolate mofetil in renal transplant patients receiving different immunosupressive combined therapy and stable after at least three months' administration. 82
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. 82
Molecular basis of pyrimidine 5'-nucleotidase deficiency caused by 3 newly identified missense mutations (c.187T>C, c.469G>C and c.740T>C) and a tabulation of known mutations 82
Mechanochemical Synthesis and Biological Evaluation of Novel Isoniazid Derivatives with Potent Antitubercular Activity. 80
From virulence factors to drug development: MbtI as an effective Mycobacterium tuberculosis target 79
PYRUVATE KINASE DEFICIENCY: MOLECULAR AND FUNCTIONAL CHARACTERISATION OF A LETHAL VARIANT 79
Antivirulence compounds: a future direction to overcome antibiotic resistance? 78
6-Hydroxy-2-methylbenzofuran-4-carboxylic Acid 77
Structural and Energetic Basis of Protein Kinetic Destabilization in Human Phosphoglycerate Kinase 1 Deficiency 76
Nitric oxide-releasing compounds for the treatment of lung infections 76
Pyruvate kinase deficiency : The genotype-phenotype association 75
Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis 75
Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents 75
Mycobacterium abscessus siderophores biosynthesis as a target to inhibit the iron uptake mechanism 74
Molecular and functional characterization of a lethal variant of pyruvate kinase deficiency 74
Pyrimidine 5'-nucleotidase activities detected in real samples by means of micellar electrokinetic chromatography. 74
Functional investigation of the antitubercular drug target Decaprenylphosphoryl-β-D-ribofuranose-2-epimerase DprE1/DprE2 complex 74
Exploring the role of the heterocyclic moiety of 5-(4-nitrophenyl)-2-furoic acid, a promising inhibitor of MbtI from Mycobacterium tuberculosis. 73
Hereditary erythrocyte pyrimidine 5'-nucleotidase deficiency: a biochemical, genetic and clinical overview 72
The redox state regulates the conformation of Rv2466c to activate the antitubercular prodrug TP053. 72
Tackling Critical Catalytic Residues in Helicobacter pylori L-Asparaginase 72
The crystal structure of Burkholderia cenocepacia DfsA provides insights into substrate recognition and quorum sensing fatty acid biosynthesis 72
Red cell pyruvate kinase deficiency: 17 new mutations of the PK-LR gene 71
Molecular Basis of Hemolytic Anemia: First Biochemical Characterization of Wild-Type and N190S Mutant Human Erythrocyte Pyrimidine 5'-Nucleotidase. 71
Two new mutations of the P5'N-1 gene found in Italian patients with hereditary hemolytic anemia: the molecular basis of the red cell enzyme disorder. 70
Investigating the Molecular Bases of the Phosphoglycerate Kinase Deficiency: Characterization ofG158V, R206P, V266M and D285V Pathological Variants. 70
PHOSPHOGLYCERATE KINASE DEFICIENCY: FUNCTIONAL PROPERTIES OF THE L89P, K191DEL, C316R AND A354P PATHOLOGICAL VARIANTS 69
Antibiotics sustainability: another issue in the fight against antimicrobial resistance. 69
CanB, a Druggable Cellular Target in Mycobacterium tuberculosis 68
L-ASPARAGINASE FROM HELICOBACTER PYLORI 68
Iron acquisition pathways as targets for antitubercular drugs. 68
Totale 9.398
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.667
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.667
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021460 0 0 0 0 0 68 19 165 42 87 63 16
2021/2022647 13 6 12 46 19 15 15 47 44 22 79 329
2022/20232.055 188 181 25 156 177 195 5 109 934 13 50 22
2023/20241.048 160 175 41 85 88 228 46 69 5 49 46 56
2024/20252.590 77 191 76 54 92 106 178 158 659 103 321 575
2025/20263.086 494 348 672 702 698 172 0 0 0 0 0 0
Totale 12.467